Molecular dosimetry of DNA and hemoglobin adducts in mice and rats exposed to ethylene oxide by Walker, V E et al.
Environmental Health Perspectives
Vol. 99, pp. 11-17, 1993
Molecular Dosimetry of DNA and
Hemoglobin Adducts in Mice and Rats
Exposed to Ethylene Oxide
by Vernon E. Walker,"23 Timothy R. Fennell,' Patricia
B. Upton,4 John R MacNeela,' and James A.
Swenberg4
Experiments involving ethylene oxide (ETO) have been used to support the concept ofusing adducts in hemoglobin as
a surrogate for DNA adducts in target tissues. The relationship between repeated exposures to ETO and the formation
of N-(2-hydroxyethyl)valine (HEtVal) in hemoglobin and 7-(2-hydroxyethyl)guanine (7-HEG) inDNA was investigated in
male rats and mice exposed by inhalation toO, 3,10,33, or 100 ppm ETO for 6 hr/day for 4 weeks, or exposed to 100 ppm
(mice) or 300ppm (rats) for 1, 3, 5,10, or 20 days (5 days/week). HEtVal was detennined by Ednan degradation, and 7-HEG
was quantitated by HPLC separation and fluorescence detection. HEtVal formation was linear between 3 and 33 ppm ET1O
and increased in slope above 33 ppm. The dose-response curves for 7-HEG in rat tissues were linear between 10 and 100
ppm ETO and increased in slope above 100 ppm. In contrast, only exposures to 100 ppmETO resulted in significant ac-
cumulation of7-HEG in mice. Hemoglobin adducts were lost at a greater rate than predicted by normal erythrocyte life
span. The loss of7-HEG from DNA was both species and tissue dependent, with the adduct half-lives ranging from 2.9
to 5.8 days in rat tissues (brain, kidney, liver, lung, spleen, testis) and 1.0 to 2.3 days in all mouse tissues except kidney (tlm
= 6.9 days). The concentrations ofHEtVal were similar in concurrently exposed rats and mice, whereas DNA from rats
had at least 2-fold greater concentrations of7-HEG than DNA from mice. Due to differences in formation, persistence,
repair, and chemical depurination, the relationships between HEtVal and 7-HEG concentrations varied with length of
exposure, interval since exposure, species, and tissue. Thus, it appears unlikely that HEtVal adducts in hemoglobin will
provide accurate predictions ofDNA adducts in specific tissues ofhumans under conditions where actual exposure scenarios
are unknown.
Introduction
Ethylene oxide (ETO) is a potent mutagen and carcinogen in
laboratory animals, but its potential to cause cancer in man is still
uncertain. In carcinogenicity bioassays, ETO caused dose-
related increases in the incidence of gliomas, peritoneal meso-
theliomas, and mononuclear cell leukemias in F344 rats (1,2)
and lymphomas and adenomas/adenocarcinomas of the lung,
uterus, harderian gland, and mammary gland in B6C3F, mice
(3). In the earliest epidemiology studies on ETO and cancer,
Hogstedt et al. (4-7) reported excesses of leukemia and lym-
phatic and stomach cancers among sterilant workers and
employees in a chemical production plant. More recently, two
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independent studies found an excess of non-Hodgkin's lym-
phoma in ETO workers (7,8). Several other epidemiological
studies have not demonstrated any association between ETO ex-
posure and cancer in workers (10-12). However, the sensitivity
ofepidemiologic studies designed to assess the potential health
hazards of environmental chemicals is seriously compromised
by the lack of reliable quantitative exposure data for individuals
in exposed populations (13). Consequently, a major goal in the
study ofenvironmental carcinogens is to identify biomarkers that
are suitable for determining dose-response relationships in ex-
posed humans.
Because genetic damage and mutation are thought to play a
critical role in chemical carcinogenesis, damage toDNA can be
used as an internal molecular dosimeter ofcarcinogen exposure
[for review see Swenberg et al. (14)]. Therefore, DNA adducts
or a validated surrogate are relevant indicators of the biologically
effective dose (molecular dose) of carcinogen. Evaluation of
these potential biomarkers over a broad dose range in experimen-
tal animals offers a means of critically assessing which bio-
markers will be useful for monitoring human exposure and for
enhancing risk extrapolation across species.
A major initiative in monitoring carcinogen exposure came
from Ehrenberg and his co-workers, who suggested measuring
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adducts in hemoglobin as a surrogate for the molecular dose of
adducts in DNA (15,16). However, as noted by Wogan (17), in-
formation concerning interrelationships between the formation
of DNA and hemoglobin adducts is very limited, and studies
designed to evaluate these relationships are needed. Thus far,
most animal experiments investigating these relationships have
used single doses of carcinogen (18).
Several experiments involving ETO have been used to support
the concept of using adducts in hemoglobin as a surrogate for
DNA adducts in target tissues. However, previous studies in-
vestigating the formation ofboth hemoglobin and DNA adducts
have used only single exposures of rats (19,20) and mice (21 ) to
ETO. The data from these studies showed a constant ratio be-
tween DNA and hemoglobin alkylation over the range ofdoses
of ETO investigated, supporting the suggestion that the deter-
mination ofthe hemoglobin dose in vvo is a valid indicator ofthe
dose to DNA in target tissues (20). However, many DNA adducts
can be lost by processes such as repair and chemical depurina-
tion (14), whereas hemoglobin adducts of ETO appear to be
stable. Therefore, it is essential to examine the relationships bet-
ween hemoglobin and DNA adduct formation in rats and mice
over a range ofexposures and times ofexposure to ETO (22-24).
The molecular dosimetry studies reviewed here demonstrate that
the ratios between DNA and hemoglobin adduct concentrations
change over time during repeated exposures to ETO and that the
nature ofthe relationship between DNA and hemoglobin alkyla-
tion is both tissue and species dependent due to differences in the
life span of the erythrocyte and differences in DNA repair.
Methods
The methodological details of these investigations have been
published elsewhere (22-24). Thus, only a briefsummary ofthe
methods is given here.
Animal Exposures
Groups of9-week-old male B6C3FI mice and F344 rats were
exposed in 8-m3 stainless-steel and glass inhalation chambers to
0, 3, 10, 33, or 100 ppm ETO for 6 hr/day for 4 weeks (5 days/
week), or exposed to 100ppm (mice) or 300 ppm (rats) ETO for
1, 3, 5, 10, or 20 days (5 days/week). In the dose-response
studies, the mice and rats were exposed concurrently in the same
exposure chambers. TheETO concentration inside each cham-
ber was monitored continuously using a Miran infrared spec-
trophotometer. At necropsy of treated and control animals,
heparinized blood was taken from each animal by cardiac punc-
ture and red blood cells were washed with isotonic saline, frozen,
and stored at -20°C until globin samples were isolated. Brains,
kidneys, leukocytes (300 ppm ETO-treated rats only), livers,
lungs, spleens, and testes were removed, frozen, and stored at
-20°C until the DNA was isolated.
Assay for N-(2-Hydroxyethyl)valine
Erythrocytes from individual animals were lysed, and globin
was isolated by extraction with acidic isopropanol and precipita-
tionwith ethyl acetate (23,25). N-(2-Hydroxyethyl)valine (HEt-
Val) in globin samples from control and treated animals was
determined by a modified Edman degradation and GC-MS
quantitation of its pentafluorophenylisothiocyanate derivative
(26). Addition ofa known amount of [2H4]ethylene oxide-treated
globin as an internal standard, prior to Edman degradation, pro-
vided a means for quantitation ofthe amount of HEtVal present
in the isolated globin samples. Derivatized samples were
analyzed by GC-MS in the negative ion chemical ionization
mode using a Finnigan 4500 GC-MS instrument equipped with
an on-column injector and a DB-5 column, with methane as the
reagent gas. The m/z 348 and m/z 352 were monitored for detec-
tion ofthe analyte and internal standard, respectively. Quantita-
tion was based on comparison of the peak area ofthe analyte to
that ofthe internal standard and comparison to a calibration curve
for HEtVal in globin.
Assay for 7-(2-Hydroxyethyl)guanine
Whole tissues from individual rats or sets of four mice were
homogenized, and DNA was isolated using an automated phe-
nolic extraction procedure (22,24). DNA samples from rats ex-
posed to 300 ppm ETO were analyzed for 7-(2-hydroxyethyl)-
guanine (7-HEG) using neutral thermal hydrolysis and acid
precipitation, cation-exchange HPLC separation, and fluo-
rescence detection (22). The detection limit for the assay was 20
pmole 7-HEG/mg DNA.
The assay for 7-HEG was subsequently improved by using
selective enrichment via Centricon 30 microconcentrators
(Amicon, Danvers, MA) in place of acid precipitation, and by
developing a new chromatography system (24). The improved
assay was used to analyze DNA from animals in the dose-
response studies and the mouse time-course study. Up to 2 mL
of each thermal hydrolysate was cooled to 4°C and filtered
through a Centricon 30 by centrifugation. The DNA backbone
was retained on the Centricon 30 ultrafiltration membrane
(30,000 molecular weight cutoff), and essentially 100% of the
7-HEG was recovered in the filtrate. The filtrates were reduced
to a 1.0-mL injection volume and chromatographed using a
hybrid RP-SCX column (250 x 5.6 mm, 60 A, 5 ym, lot no.
1990055VW; ES Industries, Marlton, NJ) eluted with 80 mM
ammonium formate, pH 2.8, with 50 % acetonitrile. 7-HEG was
quantified by measuring fluorescence intensity (excitation at 295
nm and emission at 370 nm) and comparing peak areas to a
calibration curve for 7-HEG standard. The detection limit ofthis
assay was 2 pmole 7-HEG/mg DNA.
Results and Discussion
Analysis ofglobin from control animals showed background
concentrations of HEtVal averaging 42 ± 8 and 58 ± 10 (SE)
fmole adduct/mg globin in rats and mice, respectively, while
analyis of DNA from control tissues revealed the presence of
peaks equivalent to 2-5 pmole 7-HEG/mg DNA. The 7-HEG
standard coeluted with these peaks, giving similar concentrations
using standard additions. Comparable concentrations ofHEtVal
in hemoglobin (26) and 7-HEG in lymphocytes (27) have been
found in control populations of humans and experimental
animals without known exposure to hydroxyethylating agents or
any obvious precursor.
Repeated exposures of rats and mice to ETO led to accumula-
tion ofHEtVal in hemoglobin and 7-HEG in DNA of all tissues
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examined. After 4 weeks ofexposure, the dose-response relation-
ships for HEtVal and 7-HEG were nonlinear in both rats and mice.
The dose-response curves for HEtVal were linear between 3 and
33 ppm ETO and increased in slope above 33 ppm (Fig. 1). The
concentrations of HEtVal were similar in concurrently exposed
rats and mice. A comparison of the dose-response curves for
7-HEG in DNA ofboth species showed that rats had significant-
ly greater accumulations of 7-HEG than those in similarly
exposed mice (Fig. 2). In rats, the dose-response curve for7-HEG
was linear between 10 and 100 ppm ETO (Fig. 2) and increased in
slope above 100ppm (see Fig. 6A ). In contrast, after4weeks ofex-
posureofmice to 10 and 33ppmETO, the concentrations of7-HEG
were similar to andjust above, respectively, those concentrations
found in control mouse tissues (Fig. 2). Repeated exposures to 100
ppm ETO were required todemonstrate any significant accumula-
tion of7-HEG in mouse tissues.
Exposures of rats and mice for 4 weeks (5 days/week) to 300
and 100 ppm ETO, respectively, led to an accumulation ofHEt-
Val that was 14 (rats) and 15 (mice) times greater than that found
after a single day ofexposure (Fig. 3). After cessation ofthe time-
course studies, HEtVal was lost more rapidly than would be
predicted by the normal erythrocyte life span in rats and mice
(Fig. 4). The initial phase of rapid decline in HEtVal concentra-
tions in exposed rats (Fig. 4A) was consistent with the removal
of older, more heavily alkylated populations of red blood cells,
accompanied by a burst of erythropoiesis. Moreover, evaluation
ofthe protocols used in these studies revealed that discontinuous
exposures to ETO can result in complex patterns ofhemoglobin
adduct removal (23,28), in contrast to the predictable patterns of
adduct removal observed after single exposures or exposures ex-
ceeding the life span of erythrocytes (29).
Accumulations of7-HEG were similar in target and nontarget
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FIGURE 1. Dose response for N-(2-hydroxyethyl)valine in hemoglobin ofmice
(*) and rats (*) after 4 weeks (6 hr/day, 5 days/week) ofexposures to ethylene
oxide. Data points are means ± SE (n = 5).
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FIGURE 2. Dose response for 7-(2-hydroxyethyl)guanine in DNA of rats
(A brain, 0 lung, Ol spleen) and mice (A brain, * lung, * spleen) after 4
weeks (6 hr/day, 5 days/week) of exposures to ethylene oxide. Data points are
means ± SE (n = 4).
adduct concentration in testis was 50-70% and 35-47% lower
than in other rat and mouse tissues, respectively (Fig. 3). After
cessation of exposures, two distinct patterns of 7-HEG persis-
tence were apparent among the rat and mouse tissues investigated
(Fig. 5). 7-HEG disappeared in a slow, steady fashion from DNA
of mouse kidney (tl/2 = 6.9 days) and rat lung, brain, and testis
4t/2 = 4.8-5.8 days), consistent with adduct loss primarily by
chemical depurination (24). In contrast, the loss of7-HEG from
other mouse (t12 = 1.0-2.3 days) and rat (t412 = 2.9-3.9 days)
tissues was more rapid, consistent with loss by a combination of
depurination and active removal of adducts by DNA repair.
Finally, a comparison ofthe dose-response, formation, and per-
sistence curves for each species indicated that saturation of
7-HEG repair had occurred at the concentrations ofETXO used in
the time-course studies. Furthermore, the occurrence of non-
linear dose-response curves suggested that repeated exposures
of rats and mice to lower concentrations of ETO, matching the
linear portions ofthe curves, would lead to species and tissue dif-
ferences in 7-HEG accumulation as a result of differences in
DNA repair.
DNA and Hemoglobin Adducts As
Molecular Dosimeters after Repeated
Intermittent Exposures to ETO
The nature ofthe relationships between the formation ofHEt-
Val in hemoglobin and 7-HEG in DNA during repeated ex-
posures of rats and mice to ETXO was revealed, in part, by com-
parisons ofthe shapes of the formation curves for these adducts
in each species (Fig. 3). The shape of the formation curve for
HEtVal in rats exposed to 300 ppm ETO indicated that the
hemoglobin adduct should accumulate well beyond 4 weeks with














hemoglobin and 7-HEG in DNA changed throughout repeated
exposures ofrats to ETO. Over 4 weeks ofexposure to 300 ppm
ETh, the ratio ofHEtVal:7-HEG increased by a factor of 1.8-2.6,
depending on the tissue. With additional exposures, the ratio
should continue to increase as HEtVal accumulates over the
lifetime ofthe rat erythrocyte. During exposures equivalent to or
exceeding theRBC life span, hemoglobin adduct concentrations
would reach a plateau and the HEtVal:7-HEG ratio would final-
ly become constant.
In contrast to the curves for rats, the shapes of the formation
curves for HEtVal and 7-HEG in mice exposed to 100 ppm ETO
suggested that hemoglobin adduct concentrations would ap-
proach a steady state shortly after DNA adduct concentrations
had plateaued in mouse lung (Fig. 3B). However, accurate
predictions ofthe times to steady state for 7-HEG in other mouse
tissues will require better characterization ofthe kinetics ofDNA
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FIGURE 3. Formation of N-(2-hydroxyethyl)valine in hemoglobin and 7-(2-
hydroxyethyl)guanine in DNA of rats (A) exposed to 300 ppm ethylene ox-
ide and mice (B) exposed to 100 ppm ethylene oxide for up to 4 weeks (6
hr/day, 5 days/week). Globin ([), brain (A), lung (0), leukocytes (*), spleen
(-), kidney (0), liver (A), testis (X). Data points are means ± SE (n = 4
or 5). Note that the scale ofthe Y-axes forA are adjusted so that the data points
for N-(2-hydroxyethyl)valine and 7-(2-hydroxyethyl)guanine overlap on day
I of exposure.
with published experiments showing that 4-aminobiphenyl
hemoglobin adduct accumulated in a parabolic fashion over the
life span ofthe erythrocyte (30), which is 66 days in the F344 rat
(31). In comparison, the shapes of the formation curves for
7-HEG in rat tissues suggested that this DNA adduct should ap-
proach steady-state concentrations by 4 weeks ofETO exposure.





















FIGURE 4. Comparison of the projected loss of N-(2-hydroxyethyl)valine to
the observed loss of adduct after 4 weeks ofexposure of rats (A) to 300 ppm
ethylene oxide and mice (B) to 100 ppm ethylene oxide. Projected (0,0);
observed (0,0). Data points are means ± SE (n =5). The derivation of the
curves for the projected loss of N-(2-hydroxyethyl)valine is discussed in
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350 accumulation should plateau after 9 weeks of ET() exposure.
In summary, these data demonstrate that the relationships be-
300 tween hemoglobin and DNA adduct accumulation can change
over time during repeated or intermittent exposures to elec-
trophiles, with the degree of change depending on such factors
250 as the pattern and duration of exposures, cell kinetics, and the
stability of the adducts under study. As illustrated by the figures


















FIGURE 5. Persistence of 7-(2-hydroxyethyl)guanine in DNA after 4 weeks of
exposure of rats (A) to 300 ppm ethylene oxide and mice (B) to 100 ppm
ethylene oxide. Brain (A), lung (0), leukocytes (*), spleen (U), kidney (@),
liver (A), testis (X). Data points are means ± SE (n = 3 to 5).
adduct removal during exposures ofmice to lower concentrations
ofETO. Nevertheless, the ratio ofthe concentrations ofHEtVal
and 7-HEG changed throughout repeated exposures of mice to
100 ppm ET1O. Over the 4 weeks of exposure, the ratio of HEt-
Val:7-HEG increased by a factor of 2.5-4.2, depending on the
tissue.
During repeated exposures to ETO, there should also be tissue-
dependent differences in the relationship between HEtVal and
7-HEG due to tissue differences in DNA repair. For example, the
half-lives for 7-HEG in various rat tissues (Fig. 5A) indicated
that, during exposures that do not saturate repair, the adduct
should reach a steady state by 2 weeks in leukocytes and spleen
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FIGURE 6. Comparison of the dose response for N-(2-hydroxyethyl)valine in
hemoglobin and 7-(2-hydroxyethyl)guanine in DNA of rats (A) and mice (B)
exposed to ethylene oxide for4 weeks (6 hr/day, 5 days/week) . Globin (O),
brain (A), lung (0), spleen (U). Data points are means ± SE (n = 3 to 5).
Note that the scale of the X-axis is different in A and B and that the scale of
the Y-axes in A are adjusted so that the data points for N-(2-hydroxy-






nature ofthe nonconstant relationship between the hemoglobin
and DNA adducts can be both tissue and species dependent.
Implications for Human Biomonitoring
In human biomonitoring, quantitative analysis ofDNA and
hemoglobin adducts serves two related goals, assessment ofthe
internal dose and evaluation of the effects produced in target cells
by a putative carcinogen (29). The results of the molecular
dosimetry studies in rats and mice exposed to ETO have con-
firmed certain principles concerning relationships between DNA
and hemoglobin adducts and their use in exposure monitoring
and risk assessment (18,29).
First, these data demonstrate that considerable knowledge
concerning the stability and repair ofDNA adducts in different
tissues and at different exposure concentrations is needed before
any predictions can be made from DNA biomonitoring data from
exposed people. Thus far, no information is available concern-
ing the formation and removal of 7-HEG from DNA of ETO-
exposed people or ETO-treated human tissues.
Second, the kinetics ofhemoglobin adduct removal following
intermittent and variable exposures are much more complex than
those associated with single or continuous exposures (23,28).
The pattern of hemoglobin adduct removal can be complicated
further by exposures that influence erythrocyte life span or
erythropoiesis. As a possible example, chronic exposure to
tobacco smoke could induce mild, cumulative toxic effects in
erythrocytes and explain, in part, the faster-than-expected
decline in 4-aminobiphenyl hemoglobin (4ABP-Hb) adducts
seen in smokers enrolled in a withdrawal program (32). In the
first 3 weeks ofwithdrawal, the rate ofadduct decline was most
compatible with an erythrocyte life span of 80 days, compared
to the normal life span of 120 days. Maclure and co-workers (32)
suggested that some degradation of4ABP-Hb adduct might oc-
cur over time, but it is also possible that the life span of eryth-
rocytes was reduced in smokers due to the combined alkylating
potency of such tobacco constituents as ETO, acrylonitrile,
4-aminobiphenyl, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK). Compensatory erythropoiesis in these
smokers would certainly be sufficient to maintain normal red
blood cell counts and could be evaluated by assaying for
reticulocytes. Therefore, appropriate information on the pattern
of exposures and red blood cell integrity should be considered
essential when assessing the significance of adduct values
obtained in monitoring humans exposed to hemoglobin
alkylating agents.
Third, due to differences in formation, persistence, repair, and
chemical depurination of 7-HEG and toxicokinetic effects on
erythrocytes, the relationships between 7-HEG and HEtVal con-
centrations will vary with length ofexposure, interval since ex-
posure, species and tissue or even cell type. Thus, it appears
unlikely that HEtVal adducts in hemoglobin will provide accurate
predictions ofDNA adducts in specific tissues ofhumans under
conditions where actual exposure scenarios are unknown. Ifthe
exposure conditions are known, the HEtVal and exposure data
could be incorporated into a computer model to describe the
kinetics ofaccumulation and removal ofadducts formed in vivo
in complex exposure scenarios. Fennell and co-workers (28)
have recently developed such a computer model for the formation
and removal of hemoglobin adducts. Extension of this type of
model to include delineations ofDNA repair/loss kinetics of ad-
ducts in human tissues and cells could provide a means of
estimating genetic damage in exposed individuals using DNA
and/or hemoglobin adduct measurements. Limited data from rat
studies have already been incorporated into a preliminary
physiologically based pharmacokinetic model for simulation of
ETO adduct concentrations in the rat (33).
Little is currently knownaboutthe relationship between 7-HEG
and the induction of mutations and cancer by ETO. Although
similar concentrations of7-HEG have been found in target and
nontarget tissues of rats and mice after single ET3O exposures
(19-21) and multiple exposures that saturated DNA repair
(22,24), thetissue-dependent variation in the half-life for this ad-
duct indicates that there will be species, tissue, and even cell dif-
ferences in the extentof7-HEG accumulation during multiple ex-
posures to lower concentrations ofETO. However, other critical
factors appear to be involved in the species and tissue specificity
for tumor induction by this chemical. For instance, the location
of lesions in the genome and tissue susceptibility or resistance
genes represent importantdeterminants that could quantitative-
ly affect the dose-response relationship for ET1-induced tumor-
igenesis. Identification ofthese events and their relationships to
7-HEG or HEtVal will require additional research.
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